Early Positive Results in Ongoing Gene Therapy Trials for Wet AMD and Stargardt’s
August 16, 2012
Last week, Oxford BioMedica and its partner Sanofi announced positive results in their ongoing gene therapy clinical trials for wet AMD and Stargardt’s disease. In an interim review of their Phase I (RetinoStat) and Phase I/IIa (StarGen) trials, the Data Safetly Monitoring Board (DSMB), an independent panel of specialists in the fields of ophthalmology, virology and vectorology, gave the go ahead to proceed to a final patient cohort in the Phase I study in the case of the RetinoStat trial, and to a third patient cohort in the Phase I/IIa study of the StarGen trial.
To read more about the status of these clinical trials, please follow this link.
You might also enjoy...
- ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD
- ACT Adds Third Clinical Trial Site for Testing Treatment of Dry Macular Degeneration With Embryonic Stem Cells
- Stem Cells/Cell Therapy in Ophthalmology Tables Updated
- Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells
- More on the NeoVista Epi-Retinal Strontium 90 Treatment for Wet AMD
Jump down to form below to submit your own comments